Dextran Products Wins Awards for Water Conservation Efforts
TORONTO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Polydex Pharmaceuticals Limited (OTC MKTS:POLXF) (the “Company”) operating as Dextran Products, today announced it has received two awards for water conservation efforts.
For several years, Management has been focusing on maintaining profitability while improving production efficiencies in order to meet worldwide demand for the company’s signature core dextran products.
Recently it became clear to George Usher, CEO and President of Polydex Pharmaceuticals, that cost savings could be achieved through water conservation. “We go through about 105 million litres of water per year,” Mr. Usher explained “and I had been hearing of a growing trend to conserve water and hence utility costs in the process. Ultimately in collaboration with Partners in Project Green and Enviro Stewards , we started investigating systems to re-direct water, with the goal of reducing costs in the process. Initially the intent was simply to save money; however we are now enjoying the process of going green as an added benefit.”
The Company has recently been honored with two Awards for its achievements and visionary efforts.
Mr. Usher continued, “Over the course of the past year, we made major improvements to the production equipment, including a new boiler, re-tubing of the existing boiler and several other modifications as part of our investment into the future. As a result we are hoping for important savings in utility costs, although these are difficult to quantify at present. Receiving awards for those efforts is an unexpected and encouraging benefit.”
The Company’s publicly traded shares continue to be quoted on the OTC Pink Sheet platform ().
The Company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at . Information about the Company’s products is available at
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the manufacture of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market. Company website:
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like “may”, “could”, “might”, “expect”, “anticipate”, “believe”, or similar words. Actual events or results may differ materially from the Company’s expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities as results of pending or future clinical trials. Other risk factors discussed in the Company’s financial reports may also affect the actual results achieved by the Company.
Contact:
Investor Relations: North Arm Capital Services, Linda Hughes, 1-877-945-1621, ( )
